Supported projects by the Foundation since its creation in 2008
Cystic fibrosis is the most common fatal genetic disease in western countries. It affects one out of every 2,500 births and patients have a 35-year life expectancy. There is currently no cure for cystic fibrosis. The Université Libre de Bruxelles studies the possibility for a treatment thanks to the discovery of a new type of antibodies, the nanobodies, smaller than usual antibodies.
The Air Liquide Foundation supports the Institut Pasteur of Paris to fight pulmonary bacterial infections. The objective of the research work is to study the action of proteins, antimicrobial peptides, on bacteria responsible for respiratory infections.
The Air Liquide Foundation supports a research project led by the Centre d’Expertise en Altitude (EXALT) regarding oxygenation in high altitude environments.The study tracked fifty volunteers in the Himalayan mountains, about 5500 meters above sea level, and measured cerebral and cardiac effects at high altitudes and also sleep cycle changes. A mask that increases expiratory pressure was also experimented, with the goal of raising blood oxygen concentration and thus facilitating the adaptation of organisms at high altitude.
Air Liquide Foundation